Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Business News » Fluidigm Q3 Revenues Jump 50 Percent Driven by COVID-19 Testing

Fluidigm Q3 Revenues Jump 50 Percent Driven by COVID-19 Testing

Nov 05, 2020
|
staff reporter

NEW YORK – Fluidigm reported after the close of the market on Thursday that its third quarter revenues jumped 50 percent year over year driven largely by products related to COVID-19 testing and research.

For the three months ended Sept. 30, 2020, Fluidigm tallied $39.9 million in revenues compared to $26.5 million a year ago and well above analysts' consensus estimate of $32.5 million.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Early Trial Responses

A small, early-stage trial of a combination therapy for brain cancer reports favorable responses in two patients, according to the Guardian.

Hurdles to Genomic Surveillance

Nature News writes that viral genomic surveillance in the US faces systemic issues.

Boosts Requested

President Joe Biden is seeking an increase in federal spending, including higher budgets for the National Institutes of Health and Centers for Disease Control and Prevention.

PLOS Papers on Chronic Pain, Indigenous Populations in Mexico, SARS-CoV-2 Mutations

In PLOS this week: sex-stratified genome-wide association study of chronic pain, sequencing data from Indigenous Mexican groups, and more.

Apr
13
Featured Webinar

An Opportunity Arises from the Pandemic: The Promise of Targeted NGS for SARS-CoV-2 Detection

Sponsored by
Beckman Coulter Life Sciences

Mitigation of the SARS-CoV-2 pandemic will continue to require innovative solutions. This webinar will outline how Fry Laboratories rapidly redeployed a next-generation sequencing (NGS) pipeline originally created for the detection and identification of bacterial, eukaryotic, and fungal infections in response to SARS-CoV-2.

Apr
15
Featured Webinar

Panel Discussion: Data Interpretation in Wastewater Surveillance for SARS-CoV-2

Sponsored by
Combinati

Detection and quantification of SARS-CoV-2 levels in wastewater can be a useful predictor of potential COVID-19 outbreaks. However, the interpretation of the surveillance data can be challenging.

Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
12
Featured Webinar

SARS-CoV-2 RNAemia Predicts Clinical Deterioration and Extrapulmonary Complications from COVID-19

Sponsored by
Combinati

This webinar will discuss a recent study that characterized the relationships between SARS-CoV-2 RNAemia and disease severity, clinical deterioration, and extrapulmonary complications (EPCs).

What's Popular?

In PCR

  1. DiaSorin to Acquire Luminex for $1.8B

  2. CLIA Waiver in Hand, Binx Health Targeting Retailers, Urgent Care Centers With STI Tests

    Premium

  3. Armed With $55M in New Funding, Nucleix to Further Invest in Early-Stage Lung Cancer Dx

    Premium

  4. Hologic to Acquire Finnish MDx Firm Mobidiag for Approximately $795M

  5. Novacyt in Dispute with UK Department of Health and Social Care Over Coronavirus Test Contract

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.